Last reviewed
7/8/26 → 7/10/26
Conviction●●●●○4 of 5
Research target$363.12Snapshot target
Thesis statusSTRENGTHENEDLast reviewed 7/10/26
Market cap$38.66BSnapshot value
Research history
See all NTRA changes ↗What changed
Conviction
1 → 4
Target
— → $363.12
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Last reviewed
Not reviewed → 7/8/26
Target
$363 → $363.12
Genetic testing + MRD pure-play. Signatera (MRD) and Panorama (NIPT) drive recurring test-volume revenue. High growth but negative earnings.
Q1 2026 >1M tests processed; FY2026 revenue guide raised to $2.74B-$2.82B; continued Signatera and Fetal Focus adoption; payer coverage / label expansion.
Thesis weakens if reimbursement stalls, Signatera adoption decelerates, or competition compresses price / margin leverage before durable cash generation arrives.
bullish; X discussion centered on Signatera adoption, FY26 guidance raise, and first-quarter volume strength
Snapshot · 7/10/26🟢 Lean-Bull · ins-$5.7M · 13F 13+/11- · short↓0.09
Snapshot · 7/10/26